Movatterモバイル変換

[0]ホーム
URL:

Skip to main content

Advertisement

Springer Nature Link
Log in

A six-month, placebo-controlled trial ofd-cycloserine co-administered with conventional antipsychotics in schizophrenia patients

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

d-Cycloserine, a partial agonist at the glycine site of theN-methyl-d-aspartate receptor, has demonstrated inconsistent efficacy for negative and cognitive symptoms of schizophrenia. The strongest evidence for efficacy has come from studies usingd-cycloserine at a dose of 50 mg/day added to conventional antipsychotics in trials of 8 weeks duration or less.

Objective

To assess the efficacy for negative symptoms and cognitive impairment ofd-cycloserine augmentation of conventional antipsychotics in a 6-month trial.

Methods

Fifty-five schizophrenia patients with prominent negative symptoms, treated with conventional antipsychotics, were randomly assigned to treatment withd-cycloserine 50 mg/day or placebo for 6 months in a double-blind, parallel group design.

Results

Twenty-six subjects completed the 6-month trial; drop-out rates did not differ between treatment groups.d-Cycloserine treatment did not differ from placebo treatment on any primary outcome measure at 8 or 24 weeks, including response of negative symptoms and performance on a cognitive battery. Serumd-cycloserine concentrations did not correlate with response of negative symptoms.

Conclusion

d-Cycloserine did not exhibit therapeutic effects in this trial, possibly reflecting the high drop-out rate, a narrow range of therapeutic serum concentrations, a modest magnitude of therapeutic effect for the selected outcome measures, or loss of efficacy over time. Becaused-cycloserine is a partial agonist with relatively low affinity for the glycine site, the magnitude of potential therapeutic effect may be smaller than that achieved by the higher-affinity full agonists, glycine andd-serine.

This is a preview of subscription content,log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
¥17,985 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Japan)

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  • Andreasen N (1984) Modified scale for the assessment of negative symptoms. National Institutes of Mental Health publication ADEM 9–102

  • van Berckel BN, Hijman R, van der Linden JA, Westenberg HG, van Ree JM, Kahn RS (1996) Efficacy and tolerance ofd-cycloserine in drug-free schizophrenic patients. Biol Psychiatry 40:1298–1300

    Article PubMed  Google Scholar 

  • van Berckel BNM, Evenblij CN, van Loon BJAM, Maas MF, van der Geld MAM, Wynne HJ, van Ree JM, Kahn RS (1999)d-Cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology 21:203–210

    Article PubMed  Google Scholar 

  • Cascella NG, Macciardi F, Cavallini C, Smeraldi E (1994)d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J Neural Transm [Gen Sect] 95:105–111

    CAS  Google Scholar 

  • Chessell I, Procter A, Francis P, Bowen D (1991)d-Cycloserine, a putative cognitive enhancer, facilitates activation of theN-methyl-d-aspartate receptor-ionophore complex in Alzheimer brain. Brain Res 565:345–348

    Article CAS PubMed  Google Scholar 

  • Crane GE (1959) Cycloserine as an antidepressant agent. Am J Psychiatry 115:1025–1026

    CAS PubMed  Google Scholar 

  • Danysz W, Parsons C (1998) glycine andN-methyl-d-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 50:597–664

    CAS PubMed  Google Scholar 

  • D’Souza DC, Gil R, Cassello K, Morrissey K, Abi-Saab D, White J, Sturwold R, Bennett A, Karper LP, Zuzarte E, Charney DS, Krystal JH (2000) IV glycine and orald-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol Psychiatry 47:450–462

    Article CAS PubMed  Google Scholar 

  • Evins A, Fitzgerald S, Wine L, Roselli R, Goff D (2000) A placebo controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 157:826–828

    Article CAS PubMed  Google Scholar 

  • Ganote C, Peterson D, Carone F (1974) The nature ofd-serine-induced nephrotoxicity. Am J Pathol 77:269–282

    CAS PubMed  Google Scholar 

  • Goff DC, Coyle JT (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367–1377

    Article CAS PubMed  Google Scholar 

  • Goff DC, Tsai G, Manoach DS, Coyle JT (1995) Dose-finding trial ofd-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152:1213–1215

    CAS PubMed  Google Scholar 

  • Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT (1996)d-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 153:1628–1630

    CAS PubMed  Google Scholar 

  • Goff D, Henderson D, Evins A, Amico E (1999a) A placebo-controlled crossover trial ofd-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 45:512–514

    Article CAS PubMed  Google Scholar 

  • Goff D, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld D, Hayden D, McCarley R, Coyle J (1999b) A placebo-controlled trial ofd-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56:21–27

    Article CAS PubMed  Google Scholar 

  • Guy W (1976) ECDEU Assessment manual for psychopharmacology. US Department of Health, Education, and Welfare

  • Hamilton MA (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62

    CAS PubMed  Google Scholar 

  • Heinrichs DW, Hanlon TE, Carpenter WT (1984) The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10:388–396

    CAS PubMed  Google Scholar 

  • Henderson G, Johnson JW, Ascher P (1990) Competitive antagonists and partial agonists at the glycine modulatory site of the mouseN-methyl-d-aspartate receptor. J Physiol 430:189–212

    CAS PubMed  Google Scholar 

  • Heresco-Levy U, Javitt D (2004) Comparative effects of glycine and d-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res 66:89–96

    Article PubMed  Google Scholar 

  • Heresco-Levy U, Javitt D, Ermilov M, Mordel C, Horowitz A, Kelly D (1996) Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610–617

    CAS PubMed  Google Scholar 

  • Heresco-Levy U, Javitt DC, Ermilov M, Silipo G, Shimoni J (1998) Double-blind, placebo-controlled, crossover trial ofd-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmacol 3:131–135

    Article  Google Scholar 

  • Heresco-Levy U, Javitt D, Ermilov M, Mordel C, Silipo G, Lichenstein M (1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56:29–36

    Article CAS PubMed  Google Scholar 

  • Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC (2002) Placebo-controlled trial ofd-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry 159:480–482

    Article PubMed  Google Scholar 

  • Javitt DC, Zylberman I, Zukin SR, Heresco LU, Lindenmayer JP (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234–1236

    CAS PubMed  Google Scholar 

  • Jones LR (1956) Colorimetric determination of cycloserine, a new antibiotic. Anal Chem 28:39–41

    CAS  Google Scholar 

  • Jones BN (1986) Amino acids by ophthaldialdehyde precolumn derivatization and reverse-phase HPLC. In: Shively JE (ed) Method of protein microcharacterization. Humana, Clifton, pp 121–151

    Google Scholar 

  • Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276

    CAS PubMed  Google Scholar 

  • Kendig IV, Charen S, Lepine LT (1956) Psychological side-effects induced by cycloserine in the treatment of pulmonary tuberculosis. Am Rev Tuberc 73:438–441

    CAS PubMed  Google Scholar 

  • Kirkpatrick B, Buchanan R, McKenney P (1989) The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 30:119–123

    Article CAS PubMed  Google Scholar 

  • Luborsky L (1962) Clinicians’ judgments of mental health. Arch Gen Psychiatry 7:407–417

    CAS PubMed  Google Scholar 

  • Potkin S, Jin Y, Bunney B, Costa J, Gulasekaram B (1999) Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 156:145–147

    CAS PubMed  Google Scholar 

  • Simeon J, Fink M, Itil T, Ponce D (1970)d-Cycloserine therapy of psychosis by symptom provocation. Comp Psychiatry 11:80–88

    Article CAS  Google Scholar 

  • Simpson GM, Angus JWS (1970) Drug-induced extrapyramidal disorders. Acta Psychiatr Scand Suppl 212:11–19

    CAS PubMed  Google Scholar 

  • Tsai G, Yang P, Chung L-C, Lange N, Coyle J (1998)d-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44:1081–1089

    Article CAS PubMed  Google Scholar 

  • Tsai G, Yang P, Chung L-C, Tsai I-C, Tsai C-W, Coyle J (1999)d-Serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 156:1822–1825

    CAS PubMed  Google Scholar 

  • Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH (1990)d-Cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res 510:158–160

    Article CAS PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by PHS RO1 MH54245, K24 MH02025, and P50 MH60450.

Author information

Authors and Affiliations

  1. Schizophrenia Program, Massachusetts General Hospital, Boston, Mass., USA

    Donald C. Goff, David C. Henderson, Oliver Freudenreich, A. Eden Evins & Iftah Yovel

  2. Freedom Trail Clinic, 25 Staniford St, Boston, MA, 02114, USA

    Donald C. Goff

  3. Harvard Medical School, Boston, Mass., USA

    Donald C. Goff, Vivian Shih, David C. Henderson, Oliver Freudenreich, A. Eden Evins, Iftah Yovel & David Schoenfeld

  4. Bedford Veteran’s Affairs Medical Center, Boston University Medical School, Boston, Mass., USA

    Lawrence Herz

  5. Lemuel Shattuck Hospital, Tufts Medical School, Boston, Mass., USA

    Thomas Posever

  6. Pediatric Neurology Service, Massachusetts General Hospital, Boston, Mass., USA

    Vivian Shih

  7. McLean Hospital, Belmont, Mass., USA

    Guochuan Tsai

  8. Biostatistics, Massachusetts General Hospital, Boston, Mass., USA

    Hui Zhang & David Schoenfeld

Authors
  1. Donald C. Goff
  2. Lawrence Herz
  3. Thomas Posever
  4. Vivian Shih
  5. Guochuan Tsai
  6. David C. Henderson
  7. Oliver Freudenreich
  8. A. Eden Evins
  9. Iftah Yovel
  10. Hui Zhang
  11. David Schoenfeld

Corresponding author

Correspondence toDonald C. Goff.

Rights and permissions

About this article

Cite this article

Goff, D.C., Herz, L., Posever, T.et al. A six-month, placebo-controlled trial ofd-cycloserine co-administered with conventional antipsychotics in schizophrenia patients.Psychopharmacology179, 144–150 (2005). https://doi.org/10.1007/s00213-004-2032-2

Download citation

Keywords

Access this article

Subscribe and save

Springer+ Basic
¥17,985 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Japan)

Instant access to the full article PDF.

Advertisement

[8]ページ先頭
©2009-2025 Movatter.jp